To measure exclusion of elderly adults from randomized trials studying drug interventions for ischemic heart disease (IHD) and describe the characteristics of these trials. DESIGN: Cross-sectional analysis. SETTING: Interventional clinical trials studying a drug intervention for IHD that started in 2006 and after were identified in ClinicalTrials.gov. Data were extracted on study features, including age-based inclusion criteria. Data on participants and their age distribution were collected from trial publications, investigator inquiry, and result data in ClinicalTrials.gov. PARTICIPANTS: Individuals aged 65 and older. MEASUREMENTS: Proportion of trials excluding individuals based on age, mean age of trial participants, and proportion of enrolled participants aged 65 and older and 75 and older. RESULTS: Of 839 identified trials, 446 (53%) explicitly excluded elderly adults. The most-frequent upper age limits were 80 (n = 164) and 75 (n = 114), with a median upper age limit of 80 (interquartile range 75-80). Trials with upper age limit exclusions tended to be smaller (median number of participants 100 vs 201, P < .001) and were more likely to be funded primarily by nonindustry sources (78.3% vs 70.0%, P = .006). The overall mean age of trial participants was 62.7 (mean maximum age 74). The estimated proportion of participants aged 65 and older was 42.5% and the estimated proportion aged 75 and older was 12.3%.
I
ndividuals age 65 and older account for 14% of the U.S. population, but bear a large and disproportionate amount of the healthcare burden. 1, 2 More than 60% of individuals with cancer, for example, and nearly 65% of those hospitalized with heart disease are age 65 and older. 3, 4 Overall, this age group consumes more than onethird of total U.S. personal healthcare expenses every year and 30% of all prescription drug costs, 2 but there is strong evidence that elderly adults are persistently excluded from or underrepresented in clinical trials for a range of conditions, including osteoarthritis, diabetes mellitus, and various types of cancer. [5] [6] [7] As many as half of all clinical trials have explicit upper age limitations, and others limit participation of older adults based on indirect exclusion criteria such as comorbid conditions, cognitive impairment, and polypharmacy. 5, [8] [9] [10] Ischemic heart disease (IHD) is a leading and increasing healthcare burden in elderly adults worldwide, resulting in more than 900,000 deaths annually in the United States alone. 11, 12 Many more adults live with chronic symptoms and disability related to angina pectoris, nonfatal myocardial infarction, and ischemic heart failure. 11 Age-specific pathophysiological processes and unique features of disease management in elderly adults require treatment decisions that are carefully made for this population. 13, 14 A number of trials examining cardiovascular disease over the past decade have specifically focused on the study of elderly persons, but many trials-including those influencing current treatment guidelines-study primarily younger individuals. 13, 15, 16 Quantifying this gap and identifying the types of trials most likely to exclude elderly adults may inform policies addressing research needs. The aim was to measure the extent to which elderly persons are excluded from randomized trials studying drug interventions for IHD and describe the characteristics of these trials.
METHODS

Search Strategy and Inclusion Criteria
Clinical trials were selected from ClinicalTrials.gov, a publicly accessible, web-based registry that the National Institutes of Health administers. As a result of federal legislation and journal editor policies mandating trial registration before participant enrollment, prospective trial registration has become standard practice. 17, 18 ClinicalTrials.gov is the most comprehensive trial registry and holds data on approximately 218,000 trials, making it a powerful tool for examination of research activity and practices.
ClinicalTrials.gov was searched on a single day (January 15, 2016) for interventional trials addressing IHD using the term "ischemic heart disease" in the condition field of the registry's advanced search form. Studies were considered eligible if they were randomized controlled trials assessing drugs with a start date of January 1, 2006, or later. Trials that were terminated or withdrawn were excluded, as were trials specific to pediatric and adolescent populations, pregnancy and reproduction, or sexually transmitted diseases. 19 All trials were manually reviewed to ensure that they studied the treatment or prevention of IHD and that they met all inclusion criteria.
Collection of Participant Age Data
Publications describing trial results were sought for each of the trials in the study cohort. The "publication" section of ClinicalTrials.gov was searched first, and if a publication was not identified in the trial entry, Medline was searched in PubMed without language restrictions using a systematic protocol. 20, 21 A trial was considered published if a peer-reviewed publication reporting on trial results was identified. If multiple publications were identified for a single trial, each one was reviewed to identify relevant participant age data.
If a publication was not identified or did not contain all the required data for the analysis, attempts were made to contact the investigators. E-mail addresses for investigators were identified in ClinicalTrials.gov, in prior publications, and through online searches. A standard e-mail was sent to investigators, with one reminder sent 2 weeks later if no response was received. For industry-sponsored trials, if no investigator e-mail address was available or no response was received after a total of 4 weeks, an attempt was made to contact the pharmaceutical company using a company e-mail address or online form on the company website. Finally, if it was not possible to identify a publication or to obtain all relevant data for a trial, results were searched for in the ClinicalTrials.gov database.
Data Extraction for Trial Characteristics
Data on trial characteristics were extracted from ClinicalTrials.gov, including year of registration, study start and completion dates, primary funding source, trial phase, primary outcome, sample size, participant age eligibility criteria, and characteristics of study design (e.g., comparator type, number of centers; Appendix S1). The sample size listed in the registry entry initially represents the anticipated enrollment number, and investigators can update it to reflect the enrollment figure at the end of the study. Because this field is not consistently updated, and studies were examined at various stages of conduct, sample size is used to refer to anticipated or actual enrollment.
For each publication matched to a trial, the total number of participants enrolled was recorded, and data were extracted on age distribution of participants, including minimum and maximum ages, mean AE standard deviation (SD) or median (interquartile range (IQR)) age, and number of participants above specific age thresholds. Data were collected for the entire study population and for each of the study arms when available.
Statistical Analysis
Descriptive statistics were used to present the proportion of trials excluding elderly persons, the distribution of upper age limits, and the characteristics of the trials with and without upper age limits. When information on upper age limit was not available, the maximum age of participants enrolled was estimated as mean age + 2 SDs (Appendix S2) 5 . Univariate analysis with chi-square tests was used for categorical variables and two-sided t-tests or Mann-Whitney tests for continuous variables to examine the association between trial characteristics and explicit exclusion of elderly persons. Logistic regression was performed to test for trends over time in prevalence of exclusion of elderly adults, with upper age limit as the dependent variable and year of study registration as the independent variable. Multivariate logistic regression was also performed with all variables found to be significant in the univariate tests to further examine factors predicting exclusion of elderly persons. Forward and backward stepwise procedures were used, and the Hosmer-Lemeshow goodness of fit test was considered. Two-sided P < .05 was considered statistically significant.
The mean age of the entire enrolled trial population was calculated as a weighted mean based on the sample size of each trial, and a combined SD was calculated based on the mean age of the entire cohort and the sample size, SD, and mean age of each trial. 22 Different formulas were used for these calculations according to sample sizes (Appendix S2). 22, 23 The proportions of participants above specific age thresholds enrolled in the trials were calculated using age distribution information and the cumulative distribution function (Appendix S2). For these calculations, it was assumed that mean age and SD were derived from a truncated normal distribution, because each trial has a lower age limit for the enrolled population (whenever not mentioned, a lower age limit of 18 was assumed) or lower and upper age limits. [24] [25] [26] All statistical analyses were conducted in SPSS version 23.0 (IBM Corp., Armonk, NY).
RESULTS
Characteristics of Trials and Exclusion of Elderly Persons
Three thousand seven hundred seventy-seven registered interventional trials studying IHD were identified, 839 of which met the inclusion criteria and were randomized controlled trials of drug interventions ( Figure 1 ). Nonindustry sponsors were the primary funders of 74% of these trials, and 60% were conducted at single centers (Table 1) . Sixty-eight percent were Phase 3 or 4 trials, and 55% included a safety outcome. Only 23% had sample sizes of 500 or more, with a median of 120 subjects per trial. The most-common specific drug classes studied were antithrombotic agents (n = 355 trials), lipid-modifying agents (n = 132 trials), and antihypertensive medications (n = 67 trials).
Four hundred forty-six trials (53%) explicitly excluded elderly persons. The most-frequent upper age limits were 80 (n = 164) and 75 (n = 114), with a median upper age limit of 80 (IQR 75-80) ( Figure S1 ). Overall, 43% (n = 361) of the trials had an upper age limit of 80 or even lower. Of trials that did not have an upper age limit and for which the maximum age of participants could be identified or imputed (n = 200), 17% (n = 34) had enrolled no participants aged 80 and older. Logistic regression indicated a small but significant increase in the proportion of trials that excluded elderly persons over the study period (odds ratio (OR)=1.06 per year, 95% confidence interval (CI)=1.01-1.12, P = .02) (Figure 2 ). When the analysis was limited to 2008 through 2015 (to address potential biases in early adoption of ClinicalTrials.gov), there continued to be a significant trend, with increased exclusion of elderly persons over time (OR = 1.07 per year, 95% CI = 1.003-1.15, P = .04) Several characteristics were associated with trials that excluded elderly persons (Table 1) . Nonindustry sources were more likely to be the primary funders of trials with upper age limit exclusions, and trials with upper age limit Randomized controlled trials studying drug interventions for the treatment of ischemic heart disease (N=839)
Interventional trials in ClinicalTrials.gov identified using search term "ischemic heart disease" (N=3777)
Trials excluded based on manual review (N=2938):
Terminated or withdrawn (N=279) Start date missing (N=27) Start date before Jan 1, 2006 (N=681) Non-randomized design (N=624) Not about treatment or prevention of ischemic heart disease (N=142) Not a drug trial (N=1185) Trials excluded due to missing participant age data that could not be obtained through investigator inquiry or results data in ClinicalTrials.gov (N=499):
Trial not yet completed (N=404) No trial publication identified (N=90) Publication did not provide age data (N=5)
Trial publication identified (N=303):
Provided age data (N=292) Provided partial age data, additional data obtained through investigator inquiry and/or results data in ClinicalTrials.gov (N=9) Did not provide any age data, was obtained through investigator inquiry (N=2) No publication identified (N=37):
Age data obtained through investigator inquiry (N=5) Age data obtained from results data in ClinicalTrials.gov (N=32) Trials with participant age data (N=340) Figure 1 . Flow chart for trial inclusion. Data were collected on mean age and standard deviation (or median and interquartile range) for the study population or for each treatment arm and on the number of participants above specific age thresholds. exclusions tended to be smaller, not use a multicenter design, and be shorter in duration. An additional analysis was performed focusing on trials that enrolled only individuals younger than 80 (Table S1 ). Study phase, sample size, and study duration were associated with this age restriction.
In multivariate analysis, study phase, sample size, multicenter status, and study duration remained significantly associated with use of any upper age limits ( Table 2) .
Age of Trial Participants
Publications describing trial results were identified for 308 (37%) of the trials. Based on participant age data in these publications and using additional age information obtained from investigators and from the results posted in ClinicalTrials.gov, participant age data were identified for 340 trials representing 327,672 participants. For 334 of these trials, data on mean age and SD (or median and IQR) of participants were identified. For 46 of the trials, information on proportion of participants aged 65 and older was identified, and this information was imputed for the other trials, as described above. There were similar numbers of trials with (n = 161) and without (n = 179) upper age eligibility criteria that had participant age data available. The overall mean age of participants in the trials was 62.7 (mean maximum age 74). The estimated proportion of participants aged 65 and older was 42.5%, and the estimated proportion aged 75 and older was 12.3%. Figure 3 shows the distribution of estimated proportion of participants aged 65 and older and aged 75 and older for each of the trials.
DISCUSSION
These results suggest that clinical drug trials across the spectrum of IHD are not adequately enrolling elderly adults, with more than half of the trials explicitly excluding people based on upper age limits. Overall, there has been a slight increase in such exclusions over the past 10 years, in part due to changes in certain trial characteristics. Upper age limits were most frequently set at 75 and 80, resulting in a pronounced drop in the enrollment of participants aged 75 and older compared to those aged 65 and older.
The mean age of participants in trials for IHD was 62.7, which is younger than the mean age reported for individuals seeking medical care for IHD. In a populationbased surveillance study conducted in Olmsted County, Minnesota, between 2005 and 2010, the mean age of 1,244 individuals hospitalized with acute coronary syndrome was 67.7. 27 Another large community-based study in the United States reported a mean age of 69 for 46,086 individuals hospitalized with myocardial infarction between 1999 and 2008. 28 In a national registry in Sweden, the mean age of almost 200,000 individuals admitted to coronary care units for symptoms suggestive of acute coronary syndromes between 1996 and 2008 was 71. 29 The mean age is approximately a decade older for individuals with heart failure, a common complication of coronary artery disease. [30] [31] [32] The proportion of participants enrolled in clinical trials aged 65 and older was 42.5% and of those aged 75 and older was 12.3%. These rates appear lower than the age distribution of individuals with IHD, particularly for those aged 75 and older. For instance, based on the U.S. National Health Interview Survey conducted in 2012, 55.7% of individuals with coronary heart disease were aged 65 and older. 33 Another study based on a national sample of more than 260,000 individuals undergoing percutaneous coronary intervention for acute myocardial infarction in the United States from 2001 through 2009, Figure 3 . Distribution of proportion of individuals aged 65 and older and 75 and older for each trial. There were 340 trials with data on proportion of individuals aged 65 and older and 334 trials with data for individuals aged 75 and older (six trials gave proportion for aged ≥65 but did not provide proportion for aged ≥75 or mean age and SD that could be used to calculate this proportion). The median proportion of individuals aged 65 and older was 38% (interquartile range (IQR) 26-48%, range 0-100%) and the median proportion of patients aged 75 and older was 9% (IQR 2-14%, range 0-47%).
found that 45.9% were aged 65 and older. 34 These rates are not much higher than the rate estimated for trial participants in the current study. Conversely, the divergence from population data becomes much more prominent at the 75-year threshold. For example, in a community study in Olmsted County, of 2,816 individuals hospitalized for myocardial infarction between 1987 and 2006, 39% were aged 75 and older. 35 Similarly, an analysis of 1.3 million hospitalizations for acute coronary syndrome in Canada between 1994 and 2006 revealed that 40% of individuals were aged 75 and older. 36 The current results are consistent with those of prior studies assessing the representation of elderly adults in clinical trials related to IHD. One study of 194 randomized controlled trials cited in American Heart Association guidelines for acute coronary syndromes found that the mean age of participants was 61, with 18% of trials attaining a mean participant age of 65 and older and none with a mean age of 75 and older. 16 Another study examining 11 Phase III clinical trials of individuals with non-STsegment-elevation acute coronary syndrome between 1994 and 2010 revealed that 53% of participants were aged 65 and older and that only 20% were aged 75 and older. 15 The current study adds to these findings by examining 839 randomized controlled trials conducted over the past 10 years and addressing the wide spectrum of IHD. It provides new data indicating that elderly adults continue to be excluded from the most rigorous clinical studies-randomized controlled trials-and that this practice has the greatest impact on the clinical evidence available to guide care for individuals aged 75 and older.
This study also demonstrates a registry-based approach to the ongoing assessment and monitoring of elderly adults in a large number of trials. Mandatory registration of interventional trials has led to an almost comprehensive dataset of clinical trials in ClinicalTrials.gov, which can be used to examine participant enrollment practices, including age-based exclusion. Ongoing monitoring would help inform guidance and requirements for the enrollment and study of elderly adults.
Results derived from trials on younger individuals cannot necessarily be extrapolated to elderly adults because of age-related differences in pathophysiology and unique considerations in defining person-centric therapeutic targets. 3, 37 In addition, the pharmacological characteristics and toxicity of certain medications are age specific, with lower tolerability and effectiveness in older adults. 13, 38, 39 Alternatively, claimed age differences in treatment effectiveness and harms may be spurious findings of subgroup differences that are prone to false-positive results. 40 In the absence of sufficient evidence on elderly participants, one runs the risk of missing important age-treatment interactions, as well as of falsely claiming such interactions.
Regulatory agencies have issued recommendations to encourage the study of pharmaceuticals in elderly persons. 41, 42 A guideline that the Food and Drug Administration developed in 1989 states that "there is no good basis for the exclusion of patients on the basis of age alone, or because of the presence of any concomitant illness or medication, unless there is reason to believe that the concomitant illness or medication will endanger the patient or lead to confusion in interpreting the results of the study." 41 The International Conference of Harmonization also published a guideline in 1993 recommending the inclusion of elderly adults in clinical drugs trials that are likely to be relevant in this population. 42 By contrast, the U.S. Congress in the National Institutes of Health (NIH) Revitalization Act of 1993 included provisions for the inclusion of women and minorities in clinical trials but did not include requirements for older adults. 43 The NIH should consider requiring that investigators outline plans to recruit elderly adults and provide targets for the proportions to be recruited in certain age groups in line with disease distribution in the general population. 44 One of the limitations of this study is that the exclusion of elderly adults only because of explicit age criteria was examined, whereas indirect exclusions such as the presence of comorbid conditions or functional impairments may exclude many more elderly adults. 9, 45 The additional effect of such exclusions could be indirectly documented, because it was found that many trials did not have any participants aged 80 and older even though they did not include an upper age eligibility criterion. These results may therefore underestimate the overall exclusion of elderly adults. In addition, because investigators provide the data in ClinicalTrials.gov, the information cannot be verified and includes occasional incomplete data elements. Nevertheless, data entered in the registry undergo quality assurance measures by ClinicalTrials.gov before public posting, and additional data were obtained as needed through direct contact with investigators. Nonetheless, it was not possible to obtain all participant age information from the registry or publications, and certain imputations were required. Several quality control checks were performed to examine the procedures, and these indicated that the methods and results were highly reliable (Appendix S2).
In conclusion, despite the high burden of IHD in elderly adults, the majority of drug trials for this condition continue to exclude elderly adults, with individuals aged 75 and older particularly underrepresented. Current trial practices and policies regarding the inclusion of elderly adults should be reexamined to ensure the applicability of trial findings to this growing population.
ACKNOWLEDGMENTS
Conflicts of Interest: None of the authors has any conflicts of interest to disclose. The authors have no financial relationships relevant to this article to disclose.
Financial Disclosure: Drs. Bourgeois, Ioannidis, and Mandl were supported by a grant from the National Institute on Aging, NIH (1R21AG043715).
Author contributions: Bourgeois, Mandl, Ioannidis: Study concept and design. Bourgeois, Orenstein, Ballakur, Mandl, Ioannidis: Analysis and interpretation of data. Bourgeois, Orenstein: Initial draft of manuscript. Bourgeois, Orenstein, Ballakur, Mandl, Ioannidis: Critical revision and final approval of manuscript.
Sponsor's role: The sponsor had no role in the design, conduct, writing, or decision to publish this study.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article: Figure S1 . (A) Histogram of trials according to maximum eligible age. Please note: Wiley-Blackwell is not responsible for the content, accuracy, errors, or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.
